Literature DB >> 12117357

Clinical and neuropathological characteristics of hippocampal sclerosis: a community-based study.

James B Leverenz1, Christina M Agustin, Debby Tsuang, Elaine R Peskind, Steven D Edland, David Nochlin, Lillian DiGiacomo, James D Bowen, Wayne C McCormick, Linda Teri, Murray A Raskind, Walter A Kukull, Eric B Larson.   

Abstract

BACKGROUND: Hippocampal sclerosis (HS) is a neuropathologic finding characterized by neuronal loss and gliosis in the CA-1 and subiculum of the hippocampus. Previous studies of HS have shown that this is a common postmortem finding in elderly subjects with dementia. However, these studies were from selected samples and therefore are not necessarily representative of patients seen in the general medical community.
OBJECTIVES: To examine the clinical and pathologic characteristics of HS in a community-based case series of dementia and to compare these characteristics with those observed in subjects with Alzheimer disease (AD) from the same study sample.
METHODS: One hundred thirty-four autopsy cases were available from a community-based registry of dementia. Sixteen cases (12%) had a postmortem diagnosis of HS. Thirty-two comparison control cases with a neuropathologic diagnosis of AD were selected from the same files. Each case of HS was reviewed for HS neuropathologic features, including severity, distribution, and additional pathologic processes. Blinded review of clinical characteristics for the HS and control groups was performed to assess risk factors.
RESULTS: There was a wide range of severity and distribution of HS lesions between cases and substantial variability in lesion severity and age within individual cases. Serial neuropsychologic and behavioral assessments revealed similar clinical features and rates of dementia progression between HS and AD groups. Of all neuropsychologic tests performed at enrollment, only enhanced performance on Trails A differentiated the HS from the AD group (64 seconds, 0 errors vs 114 seconds, 0.6 errors; P< or = .05). The number of AD cases with at least 1 apolipoprotein epsilon 4 allele was significantly greater than the HS cases (61% vs 31%; chi(2) = 3.81, P< or = .05). Although medical record review indicated higher frequencies of clinical stroke and neuroradiologic white matter abnormalities in the HS group, risk factors for vascular disease and neuropathologic evidence of cerebrovascular disease did not differ between the groups.
CONCLUSIONS: Our results suggest that HS is a frequent pathologic finding in community-based dementia. Individuals with HS have similar initial symptoms and rates of dementia progression to those with AD and therefore are frequently misclassified as having AD. Our clinical and pathologic findings suggest that HS has characteristics of a progressive disorder although the underlying cause remains elusive.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12117357     DOI: 10.1001/archneur.59.7.1099

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  46 in total

Review 1.  Update on Hippocampal Sclerosis.

Authors:  Juliana R Dutra; Etty P Cortés; Jean Paul G Vonsattel
Journal:  Curr Neurol Neurosci Rep       Date:  2015-10       Impact factor: 5.081

Review 2.  Alzheimer's disease is not "brain aging": neuropathological, genetic, and epidemiological human studies.

Authors:  Peter T Nelson; Elizabeth Head; Frederick A Schmitt; Paulina R Davis; Janna H Neltner; Gregory A Jicha; Erin L Abner; Charles D Smith; Linda J Van Eldik; Richard J Kryscio; Stephen W Scheff
Journal:  Acta Neuropathol       Date:  2011-04-24       Impact factor: 17.088

3.  Genomics and CSF analyses implicate thyroid hormone in hippocampal sclerosis of aging.

Authors:  Peter T Nelson; Yuriko Katsumata; Kwangsik Nho; Sergey C Artiushin; Gregory A Jicha; Wang-Xia Wang; Erin L Abner; Andrew J Saykin; Walter A Kukull; David W Fardo
Journal:  Acta Neuropathol       Date:  2016-11-04       Impact factor: 17.088

4.  Incident cognitive impairment: longitudinal changes in molecular, structural and cognitive biomarkers.

Authors:  Catherine M Roe; Beau M Ances; Denise Head; Ganesh M Babulal; Sarah H Stout; Elizabeth A Grant; Jason Hassenstab; Chengjie Xiong; David M Holtzman; Tammie L S Benzinger; Suzanne E Schindler; Anne M Fagan; John C Morris
Journal:  Brain       Date:  2018-11-01       Impact factor: 13.501

5.  CSF protein changes associated with hippocampal sclerosis risk gene variants highlight impact of GRN/PGRN.

Authors:  David W Fardo; Yuriko Katsumata; John S K Kauwe; Yuetiva Deming; Oscar Harari; Carlos Cruchaga; Peter T Nelson
Journal:  Exp Gerontol       Date:  2017-02-09       Impact factor: 4.032

6.  Hippocampal sclerosis dementia with the C9ORF72 hexanucleotide repeat expansion.

Authors:  Olga Pletnikova; Kelly L Sloane; Alan E Renton; Bryan J Traynor; Barbara J Crain; Tammy Reid; Tao Zu; Laura P W Ranum; Juan C Troncoso; Peter V Rabins; Chiadi U Onyike
Journal:  Neurobiol Aging       Date:  2014-04-18       Impact factor: 4.673

7.  Neuropathological basis of magnetic resonance images in aging and dementia.

Authors:  William J Jagust; Ling Zheng; Danielle J Harvey; Wendy J Mack; Harry V Vinters; Michael W Weiner; William G Ellis; Chris Zarow; Dan Mungas; Bruce R Reed; Joel H Kramer; Norbert Schuff; Charles DeCarli; Helena C Chui
Journal:  Ann Neurol       Date:  2008-01       Impact factor: 10.422

Review 8.  Case Studies Illustrating Focal Alzheimer's, Fluent Aphasia, Late-Onset Memory Loss, and Rapid Dementia.

Authors:  Gamze Balci Camsari; Melissa E Murray; Neill R Graff-Radford
Journal:  Neurol Clin       Date:  2016-06-03       Impact factor: 3.806

9.  Recurrent seizures in patients with dementia: frequency, seizure types, and treatment outcome.

Authors:  Satish C Rao; Gerald Dove; Gregory D Cascino; Ronald C Petersen
Journal:  Epilepsy Behav       Date:  2008-10-08       Impact factor: 2.937

10.  Risk factors and global cognitive status related to brain arteriolosclerosis in elderly individuals.

Authors:  Eseosa T Ighodaro; Erin L Abner; David W Fardo; Ai-Ling Lin; Yuriko Katsumata; Frederick A Schmitt; Richard J Kryscio; Gregory A Jicha; Janna H Neltner; Sarah E Monsell; Walter A Kukull; Debra K Moser; Frank Appiah; Adam D Bachstetter; Linda J Van Eldik; Peter T Nelson
Journal:  J Cereb Blood Flow Metab       Date:  2016-01-06       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.